Celyad Completes Safety Follow-Up Of 1 Patient Related To NKG2D CAR T-Cell Trial

(RTTNews) - Celyad (CYAD) Tuesday announced the completion of the 30-day safety follow-up of the first patient enrolled in the second cohort in the Phase I clinical trial, evaluating the safety and feasibility of its NKG2D CAR T-cell therapy, in cancer patients suffering from acute myeloid leukemia or AML or multiple myeloma or MM.

The company is engaged in the discovery and development of engineered cell therapies.

The Phase I/IIa trial is designed to assess the safety and feasibility of NKG2D CAR T-Cells. Secondary endpoints include clinical activity in two haematological indications.

Data readouts from the first 12 patients treated in the Phase I portion are expected in mid-2016. Once the recommended dose is determined, the IIa phase of the trial will enroll 12 additional patients.